On September 1, 2026 BridgeBio Oncology Therapeutics, Inc. ("BBOT") (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, reported that members of its leadership team will participate in upcoming investor conferences.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Details of the company’s participation are as follows:
Cantor Global Healthcare Conference 2026
Wednesday, September 9, 2026, at 9:45 a.m. ET
Citi’s 2026 Biopharma Back to School Conference
Thursday, September 10, 2026, at 3:00 p.m. ET
Morgan Stanley 24th Annual Global Healthcare Conference
Tuesday, September 15, 2026, at 1:50 p.m. ET
Live webcasts of the presentations will be accessible on the "Events" page of the BBOT website at View Source Replays of the webcasts will be available for at least 90 days following the event.
(Press release, BridgeBio Oncology Therapeutics, SEP 1, 2026, View Source [SID1234670514])